|
Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?
|
Dec 2012
|
Best Pract Res Clin Haematol
|
myelodysplastic syndromes (MDS)
|
|
Myelodysplastic syndromes (MDS)
|
Mar 2015
|
Best Pract Res Clin Haematol
|
myelodysplastic syndromes (MDS)
|
|
When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?
|
Dec 2013
|
Best Pract Res Clin Haematol
|
myelodysplastic syndromes (MDS)
|
|
Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes
|
Dec 2013
|
Best Pract Res Clin Haematol
|
myelodysplastic syndromes (MDS)
|
|
Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): Cause or consequence?
|
Dec 2013
|
Best Pract Res Clin Haematol
|
myelodysplastic syndromes (MDS)
|
|
Myelodysplastic syndromes: State of the art pathology, diagnosis and management
|
Dec 2013
|
Best Pract Res Clin Haematol
|
myelodysplastic syndromes (MDS)
|
|
Revisiting use of growth factors in myelodysplastic syndromes
|
May 2012
|
Asian Pac J Cancer Prev
|
myelodysplastic syndromes (MDS)
|
|
Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes
|
Jan 2017
|
Asia Pac J Clin Oncol
|
myelodysplastic syndromes (MDS)
|
|
Antibodies in the treatment of aplastic anemia.
|
Feb 2012
|
Arch Immunol Ther Exp
|
aplastic anemia
|
|
Molecular Pathophysiology of Myelodysplastic Syndromes.
|
Aug 2012
|
Annu Rev Pathol
|
myelodysplastic syndromes (MDS)
|
